波兰TOMO中医学院名誉院长、经典中医学术顾问李颉分享了海外民众对中医的需求特点。他表 示，在疾病预防、复杂性疾病治疗等领域，中医具有显著优势。据他观察，针灸和中药在国外的认可度 日益提升，外籍中医师队伍也在不断壮大。"此次带领国外学生参会，目的是让他们深入感受中医的核 心文化内涵，加深对中医的理解与感悟。" 据悉，国医新路论坛已举办三届，是由王新陆牵头创办的公益性中医学术论坛，由国医新路论坛秘 书处、李克绍伤寒学派传承基地主办，山东新中鲁中医医院承办。（周艺伟） "《伤寒论》作为中医四大经典之一，在中医学中占据至关重要的地位，素有'活人书'之称。"李克 绍伤寒学派传承人、山东新中鲁中医医院院长李树沛说，作为本次论坛的承办单位，山东新中鲁中医医 院始终以《伤寒论》等中医经典为临床指导，将传统智慧与现代诊疗相结合，致力于用纯正的中医经典 理论与方法为患者解除病痛。 "当代伤寒流派高峰论坛"暨第三届国医新路学术论坛17日在山东济南举行。来自中国、波兰、荷兰 等国家的400余位中医专家学者齐聚泉城，共同探讨伤寒流派传承发展，推动中医药文化国际交流。 国医大师、中国中医科学院学部委员王新陆接受记者采访时表示，中医源于 ...

Group 1: Health Consumption Promotion - The Ministry of Commerce and the National Health Commission, along with 12 other departments, have jointly issued a plan to promote health consumption, focusing on ten key tasks such as enhancing healthy dietary consumption and optimizing the market supply of special foods [1] - The health consumption market is expanding as public awareness of health increases, with new business models and scenarios emerging, making health consumption a new growth point for boosting overall consumption [1] Group 2: Traditional Chinese Medicine (TCM) Night Market - The TCM cultural night market in Jiangxi has become a vibrant venue, attracting young people to experience TCM through various activities such as making herbal sachets and tasting medicinal cuisine [2][3] - The night market features 150 stalls and nine exhibition areas, promoting TCM culture while meeting public demand for health and wellness [3][4] Group 3: Fitness and Sports Consumption - The "Jinling Matrix" sports complex in Nanjing offers diverse fitness activities, transforming traditional parks into multi-functional consumption spaces that combine sports, leisure, and commerce [6][7] - The integration of sports and tourism in urban parks is redefining outdoor exercise, providing comprehensive service experiences and promoting a healthy lifestyle among city residents [8] Group 4: Health Tourism and Wellness - The "Kangyang Town" in Yunnan, known for its abundant Dendrobium, has become a health tourism destination, attracting visitors with its unique offerings such as Dendrobium cuisine and traditional medical services [9][10] - The local government plans to develop new business models around health tourism, enhancing the brand's visibility and integrating various health and wellness services [11][12]

Group 1 - The event in Chengdu focused on the release of 38 government-end technology application scenario demand lists and 23 enterprise-end technology application capability lists, covering 19 strategic emerging fields including traditional Chinese medicine, aviation power, advanced energy, low-altitude economy, and artificial intelligence [1][2] - Key government-end scenarios highlighted include "Low-altitude Rural Logistics System Construction," "Tianfu Traditional Chinese Medicine Innovation Port," and "Longmen Mountain Cloud-based Sightseeing Vacation" [1] - The event aims to facilitate cooperation between supply and demand, laying the foundation for future collaborative scenario construction [1] Group 2 - The released lists emphasize the first trial and application of "new technologies and new products," addressing specific industry development needs [2] - In the traditional Chinese medicine sector, two application scenarios were introduced, including a "Digital Traditional Chinese Medicine Museum" [2] - The next steps for the city include focusing on bridging the "last mile" of technology achievement transformation and using scenario innovation as a key driver for integrating various chains and promoting effective market demand linkage [2]

Core Viewpoint - Jiangxi Province has introduced the "Implementation Plan for Promoting the Development and Growth of the Private Economy," which aims to address challenges faced by private enterprises and stimulate their internal motivation and innovation capabilities through five major actions [5]. Group 1: Clearing Obstacles to Fair Competition - The plan includes actions to implement a unified national market construction guideline, eliminate local protectionism and market segmentation, and conduct regular assessments of market access effectiveness [6]. - It emphasizes the need for fair competition reviews of major policy measures and special law enforcement actions against unfair competition [6]. - The establishment of a comprehensive performance evaluation mechanism for investment projects is also highlighted [6]. Group 2: Stimulating Private Investment - The plan proposes the creation of a "one database and three lists" system for private investment, promoting projects to private capital regularly [7]. - It encourages private enterprises to participate in national major project construction and optimizes the policy environment for their involvement [7]. - The initiative aims to expand the international market space for private enterprises and promote the creation of international brands in sectors like ceramics, traditional Chinese medicine, and new materials [7]. Group 3: Addressing Financing Challenges for Private Enterprises - The plan outlines actions to enhance financial support for private enterprises, including setting annual service targets for banks in Jiangxi [8]. - It aims to improve the financing pathways for private enterprises and increase the number of first-time loan recipients [8]. - The plan also focuses on strengthening guidance for private enterprises in listing and bond issuance [8]. Group 4: Promoting Innovation and Upgrading of the Private Economy - The plan includes the implementation of six major actions to promote technological advancement in Jiangxi [9]. - It aims to establish a nurturing mechanism for small and medium-sized enterprises and supports the digital transformation of the manufacturing sector [9]. - Collaboration between state-owned and private enterprises is encouraged to share innovation resources [9]. Group 5: Supporting the Healthy Growth of Private Economic Personnel - The plan proposes a health growth promotion plan for private entrepreneurs and the continuation of a successor training program for private enterprises [9]. - It includes the publication of a list of the top 100 private enterprises by 2025 and promotes legal compliance and integrity among private businesses [9]. - The initiative also aims to combat malicious rumors and negative portrayals of private enterprises and entrepreneurs [9].

Group 1: Smart Agriculture and Rural Revitalization - The company focuses on smart agriculture as part of its digital strategy, exemplified by the "Zhe Nong Yun" grain and oil future farm project, managing 10,000 acres of rice through a digital management platform [1] - The project has been recognized as an excellent case in national smart agriculture construction and reported by major media outlets during the 2024 spring plowing season [1] - The company has received awards for its contributions to rural revitalization, including the "Outstanding Practice Case" in the 2023 Best Practices for Rural Revitalization [2] Group 2: Agricultural Input Market and Competitive Landscape - The agricultural input market in China is characterized by a fragmented structure, with the supply and marketing cooperative system holding a dominant position [2] - The company benefits from macro policy advantages, talent mechanisms, industry leadership, resource branding, and channel network advantages in the agricultural input sector [2] - The company aims to increase market share by leveraging its competitive advantages as the agricultural input industry transitions to a more integrated service model [2] Group 3: Financial Performance and Stock Buyback - As of April 2025, the company has repurchased approximately 11.89 million shares, accounting for 2.28% of total share capital, with a total transaction amount of around 100 million yuan [4] - The company has implemented a stock buyback plan to enhance investor confidence and stabilize stock prices, with a total dividend payout exceeding 600 million yuan over the past four years [7] Group 4: New Energy Vehicle Business - In 2024, the company sold over 6,000 new energy vehicles, representing a 19% year-on-year increase and accounting for 17% of total vehicle sales [4] - The company is exploring partnerships with strong, low-risk new energy brands to expand its market presence [4] Group 5: Agricultural Social Services and Future Farms - The company has established 19 agricultural service centers in Zhejiang Province and conducted over 3,800 farmer meetings and technical promotion sessions in 2024 [5] - The "Future Farm" projects focus on the entire grain and oil industry chain, with land transfer planting areas reaching 30,000 acres [5] Group 6: Market Management and Investor Relations - The company emphasizes market management and aims to enhance its market value through quality development and investor returns, including cash dividends [7] - The company plans to optimize employee entrepreneurship mechanisms and deepen stock incentive plans to improve investor relations [7]

Group 1 - The "She Health - Meituan Women's Health Public Welfare Program" was officially launched in Shanghai, focusing on creating a health management system for over 30 working women through a collaboration between government, enterprises, and medical institutions [1][3] - Beijing Tongrentang, a representative brand of traditional Chinese medicine, emphasizes the importance of liver health for women and integrates the concept of "preventive treatment" into health management, addressing modern women's health needs [3][5] - The program aims to enhance health awareness from individual to societal levels, promoting the core idea of "soothing the liver and relieving stress" [3][5] Group 2 - The collaboration with Meituan to release the "Women's Health White Paper" is a significant initiative in response to the "Healthy China" strategy, aiming to provide more precise health services through data insights and resource integration [5] - The event featured a health consultation area where experienced traditional Chinese medicine practitioners offered personalized health solutions for issues like "liver stagnation and qi deficiency" [7] - Beijing Tongrentang's mission is to make traditional Chinese medicine accessible to everyone, ensuring that every working woman can thrive with a balanced approach to health [7]

Core Viewpoint - The passing of Shi Xue Min, a prominent figure in modern acupuncture and traditional Chinese medicine, marks a significant loss for the medical community in China and globally [1][3][4] Group 1: Contributions to Medicine - Shi Xue Min was a pioneer in acupuncture, known for his innovative "Stroke Unit" therapy, which includes treatments like acupuncture and Danqi Paralysis Capsules for stroke patients [1][3] - He developed a comprehensive treatment plan for stroke that integrates acupuncture, rehabilitation training, diet, psychology, and health education, recognized as one of the top ten projects for promotion by the National Administration of Traditional Chinese Medicine [3][4] Group 2: Academic and Research Achievements - Shi Xue Min led over 43 research projects, including the National 973 Program, and received numerous awards, including one National Science and Technology Progress Award and 33 provincial and ministerial-level awards [4] - He published over 100 papers and authored more than 50 books, contributing significantly to the academic field of traditional Chinese medicine [4] Group 3: Education and Mentorship - Shi Xue Min trained nearly 500 domestic and over 80 international doctoral and master's students, significantly impacting the education of future practitioners in traditional Chinese medicine [3][4] - His unique acupuncture training classes have seen participation from over 80,000 doctors, promoting standardized practices in acupuncture [3]

在万物并秀的五月，第四届西部跨境电商博览会于成都世纪城新国际会展中心盛大启幕，这场汇聚全球 商业智慧与资源的行业盛会，吸引了来自世界各地的目光。在这场充满机遇与挑战的舞台上，四川省清 沁诗语生物科技有限公司携旗下明星产品藏金倩角璀璨亮相，不仅展现了川企的创新实力与文化自信， 更成为本届博览会中令人瞩目的焦点。 走进博览会现场，热闹非凡的氛围扑面而来，各个展位争奇斗艳，展示着前沿的产品和先进的技术。而 在泸州馆内，四川省清沁诗语生物科技有限公司的展位以独特的设计和亮眼的产品脱颖而出，瞬间吸引 了众多参展商和参观者的驻足。 藏金倩角作为入围《了不起的国货》的国潮好物代表，承载着深厚的文化底蕴与卓越的品质。该产品依 托传统中医药智慧，精选多种珍贵天然草本植物，经过现代先进工艺精心研制而成。其不仅在产品功效 上表现出色，能够为消费者提供优质的健康护理解决方案，更在文化内涵上独树一帜，将中国传统中医 药文化与现代生活需求完美结合，展现出独特的国潮魅力。自上市以来，藏金倩角凭借其出色的品质和 良好的口碑，在市场上赢得了广泛认可，成为消费者信赖的国货精品。此次亮相西部跨境电商博览会， 更是藏金倩角迈向国际市场的重要一步，彰 ...

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential for future growth [20]. 4. Blood Products - The report highlights the strong pricing power of manufacturers in the blood products sector, driven by increased demand for immunoglobulin products [22]. 5. Vaccine Sector - The vaccine sector is facing challenges due to low birth rates, but there are opportunities in specific areas such as HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and overseas growth potential in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD sector is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drugs [37]. 9. Medical Services - The report suggests focusing on eye and dental medical service companies, anticipating a boost from consumer stimulus policies [42]. 10. Offline Pharmacies - The report indicates that leading pharmacy chains are stabilizing, with a recommendation to focus on companies with strong supply chain capabilities [45]. 11. Raw Materials - The report emphasizes the importance of quality and cost management in the raw materials sector, suggesting a focus on companies with strong product capabilities [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in the medical device sector, particularly in surgical navigation and pathology screening [51]. 13. Instrument Equipment - The report notes that the scientific instrument sector is expected to recover as demand improves and more domestic support policies are introduced [56]. 14. Low-value Consumables - The report suggests that the low-value consumables sector may see investment opportunities as the industry cycle improves [59].

Investment Rating - The report maintains a positive investment rating for the healthcare sector, particularly focusing on specific companies and segments within the industry [3]. Core Insights - The report emphasizes the recovery of medical device tenders and highlights investment opportunities in segments such as blood dialysis and ultrasound, with a focus on domestic replacements [1][2]. - It suggests that leading companies in the chain pharmacy sector are likely to increase market share due to the exit of smaller players [1]. - The report identifies several key areas for investment, including innovative drugs, CXO services, traditional Chinese medicine, vaccines, and medical devices, among others [1]. Summary by Sections 1. CXO Sector - The CXO sector is expected to see valuation recovery due to supportive innovation policies and a reduction in geopolitical risks [7]. 2. Innovative Drugs - The report notes a slight increase in the A-share chemical preparation sector and highlights recent approvals for innovative drugs, suggesting a focus on ongoing R&D progress [12][67]. 3. Traditional Chinese Medicine - The performance of the traditional Chinese medicine sector has lagged behind broader market indices, indicating potential investment opportunities as the sector stabilizes [20]. 4. Blood Products - The report highlights the demand for immunoglobulin products and the potential for price increases due to supply shortages, recommending companies with strong product lines in this area [22]. 5. Vaccine Sector - The vaccine sector is currently under pressure, but there are opportunities in specific products that may gain market share, particularly in HPV vaccines [26]. 6. Upstream Pharmaceutical Supply Chain - The report suggests focusing on companies with strong brand recognition and operational capabilities in the chemical and biological reagent sectors [28]. 7. IVD Sector - The IVD industry is expected to benefit from the implementation of centralized procurement policies, which may accelerate domestic replacements [31]. 8. Medical Devices - The report recommends attention to the domestic continuous glucose monitoring (CGM) market, particularly in relation to GLP-1 drug growth [37]. 9. Medical Services - Investment opportunities are identified in ophthalmology and dental services, with a focus on companies that can leverage consumer healthcare trends [42]. 10. Pharmacy Sector - The report indicates that leading pharmacy chains are stabilizing, and suggests focusing on companies with strong supply chain capabilities [45]. 11. Raw Materials - The raw materials sector is undergoing significant changes due to procurement policies, with recommendations for companies that can adapt to these shifts [48]. 12. Innovative Instruments - The report highlights the potential for AI applications in medical devices and the ongoing trend of domestic replacements in various medical fields [51]. 13. Instrument Equipment - The scientific instrument sector is expected to recover as demand increases, with a focus on companies that are expanding their product offerings [56]. 14. Low-value Consumables - The report notes a potential recovery in the low-value consumables sector, particularly for companies that can capitalize on emerging market trends [59].